EXHIBIT 4.7(D) THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST IN ACCORDANCE WITH RULE 24B-2 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS...Share Purchase Agreement • June 29th, 2006 • Vernalis PLC • Pharmaceutical preparations • Ontario
By and betweenLicense Agreement • June 29th, 2006 • Vernalis PLC • Pharmaceutical preparations • Delaware
and-Lease • October 31st, 2003 • Vernalis PLC • Pharmaceutical preparations • England
Country Application Application Patent No Grant Date Expiry Status No Date Date P=Pending/ G=Granted Czech Republic PV2861-93 17/06/1992 282083 27/08/1997 17/06/2012 G Czech Div 1 1505-96 24/05/1996 282061 27/08/1997 17/06/2012 G Europe A* 92204003.5 18/12/1992 603432 21/10/1998 18/12/2012 G Europe ** 92912379.2 17/06/1992 591280 09/09/1998 17/06/2012 G Finland 935842 17/06/1992 P Hungary P9303731 17/06/1992 P Ireland 922062 01/07/1992 P Kazakhstan 933243.1 17/06/1992 P Norway 93.4800 17/06/1992 304774 15/02/1999 17/06/2012 G Poland P301883 17/06/1992 169392 14/12/1995 17/06/2012 G Poland P307118 10/02/1995 169410 14/12/1995 17/06/2012 G Poland P311304 22/11/1995 171034 03/09/1996 17/06/2012 G Portugal 100620 24/06/1992 P Russia 93058534.00 17/06/1992 P Slovenia P9200125 26/06/1992 9200125 15/03/1993 26/06/2012 G Slovakia PV1319-93 17/06/1992 P Slovakia PV1054-98 05/08/1998 Ukraine 93002251 17/06/1992 P
US$50,000,000 LOAN AGREEMENT BETWEEN VERNALIS PLC AS PARENTLoan Agreement • May 13th, 2005 • Vernalis PLC • Pharmaceutical preparations • New York
AND -License Agreement • May 13th, 2005 • Vernalis PLC • Pharmaceutical preparations • New York
Exhibit 4.1 SERVICE AGREEMENT DATED 21st MARCH 2003 (1) BRITISH BIOTECH PLC (2) DR P FELLNERService Agreement • October 31st, 2003 • Vernalis PLC • Pharmaceutical preparations
As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Deposit Agreement Dated as of July 7, 1992 Amended and Restated as of August 5, 1996 Amended and Restated as of December 16, 2002Deposit Agreement • June 4th, 2007 • Vernalis PLC • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT dated as of July 7, 1992, amended and restated as of August 5, 1996, and as amended and restated as of December 16, 2002 among BRITISH BIOTECH plc2002, and as further amended and restated as of June 4, 2007 among VERNALIS PLC, an English public limited company, and its successors (herein called the Issuer), THE BANK OF NEW YORK, a New York banking corporation, as depositary hereunder and any successor as depositary hereunder (herein called the Depositary), and all Owners and holders from time to time of American Depositary Receipts issued hereunder.
EXHIBIT 4.1(o) SERVICE AGREEMENT DATED 29TH OCTOBER 2004 (1) VERNALIS PLC (2) JOHN SLATER ALLEN & OVERYService Agreement • May 13th, 2005 • Vernalis PLC • Pharmaceutical preparations
THE RIGHTS OF OWNERS OF RECEIPTS TO DIRECT THE VOTING OF SHARES MAY BE RESTRICTED AS DESCRIBED IN ARTICLES 16 AND 23 BELOW Exhibit A to Deposit AgreementDeposit Agreement • June 4th, 2007 • Vernalis PLC • Pharmaceutical preparations
The Bank of New York as depositary (hereinafter called the "Depositary"), hereby certifies that ____________________________________________________ _____________________________________, or registered assigns IS THE OWNER OF ____________________________________ AMERICAN DEPOSITARY SHARES representing deposited Ordinary Shares of 5p nominal value per share (herein called "Shares") of British Biotech plcVernalis PLC, an English public limited company (herein called the "Company"). At the date hereof, each American Depositary Share represents fortytwo (2) Shares deposited or subject to deposit under the deposit agreement at the London office of The Bank of New York, as custodian (herein called the "Custodian"). The Depositary's Corporate Trust Office is located at a different address than its principal executive office. Its Corporate Trust Office is located at 101 Barclay Street, New York, N.Y. 10286, and its principal executive office is located at One Wall Street, New York, N.Y. 10286.
EXHIBIT 4.5 THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST IN ACCORDANCE WITH RULE 24B-2 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS...Share Sale and Purchase Agreement • June 29th, 2006 • Vernalis PLC • Pharmaceutical preparations
FIRST AMENDMENT TO THE CO-PROMOTION AGREEMENT BETWEEN VERNALIS DEVELOPMENT LIMITED AND ENDO PHARMACEUTICALS INC. DATED JULY 1, 2005Co-Promotion Agreement • June 29th, 2006 • Vernalis PLC • Pharmaceutical preparations
THE RIGHTS OF OWNERS OF RECEIPTS TO DIRECT THE VOTING OF SHARES MAY BE RESTRICTED AS DESCRIBED IN ARTICLES 16 AND 23 BELOW Exhibit A to Deposit AgreementAmerican Depositary Receipt • April 23rd, 2003 • British Biotech PLC • Pharmaceutical preparations
The Bank of New York as depositary (hereinafter called the "Depositary"), hereby certifies that ____________________________________________________ _____________________________________, or registered assigns IS THE OWNER OF ____________________________________ AMERICAN DEPOSITARY SHARES representing deposited Ordinary Shares of 5p nominal value per share (herein called "Shares") of British Biotech plc, an English public limited company (herein called the "Company"). At the date hereof, each American Depositary Share represents forty Shares deposited or subject to deposit under the deposit agreement at the London office of The Bank of New York, as custodian (herein called the "Custodian"). The Depositary's Corporate Trust Office is located at a different address than its principal executive office. Its Corporate Trust Office is located at 101 Barclay Street, New York, N.Y. 10286, and its principal executive office is located at One Wall Street, New York, N.Y. 10286.
ARTICLE 1Asset Purchase and Assignment Agreement • June 29th, 2006 • Vernalis PLC • Pharmaceutical preparations • New York
SECOND AMENDMENT TO THE LICENSE AGREEMENT BETWEEN VERNALIS DEVELOPMENT LIMITED AND ENDO PHARMACEUTICALS INC. DATED JULY 14, 2004License Agreement • June 29th, 2006 • Vernalis PLC • Pharmaceutical preparations
EXHIBIT 4.7(E) THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST IN ACCORDANCE WITH RULE 24B-2 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS...Right Purchase Agreement • June 29th, 2006 • Vernalis PLC • Pharmaceutical preparations
AND VERNALIS PLCAgreement Relating to the North American Frova Assets of Elan • June 15th, 2004 • Vernalis PLC • Pharmaceutical preparations
MAY 2004 VERNALIS DEVELOPMENT LIMITED AS COMPANY IN FAVOUR OFFloating Charge • June 15th, 2004 • Vernalis PLC • Pharmaceutical preparations
Exhibit 4.4(d) SMITHKLINE BEECHAM/VERNALIS THIRD AMENDMENT AGREEMENT TO THE FROVATRIPTAN DEVELOPMENT AND LICENCE AGREEMENT DATED OCTOBER 21, 1994 This third Amendment Agreement (hereinafter "3AA") made as of the 1st day of March 2004, ("Amendment...Third Amendment Agreement • June 15th, 2004 • Vernalis PLC • Pharmaceutical preparations
AGREEMENTCo-Promotion Agreement • June 29th, 2006 • Vernalis PLC • Pharmaceutical preparations
